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Abstract Chronic kidney disease (CKD) in children is
associated with dramatic changes in the growth hormone
(GH) and insulin-like growth factor (IGF-1) axis, resulting
in growth retardation. Moderate-to-severe growth retarda-
tion in CKD is associated with increased morbidity and
mortality. Renal failure is a state of GH resistance and not
GH deficiency. Some mechanisms of GH resistance are:
reduced density of GH receptors in target organs, impaired
GH-activated post-receptor Janus kinase/signal transducer
and activator of transcription (JAK/STAT) signaling, and
reduced levels of free IGF-1 due to increased inhibitory
IGF-binding proteins (IGFBPs). Treatment with recombi-
nant human growth hormone (rhGH) has been proven to be
safe and efficacious in children with CKD. Even though
rhGH has been shown to improve catch-up growth and to
allow the child to achieve normal adult height, the final
adult height is still significantly below the genetic target.
Growth retardation may persist after renal transplantation
due to multiple factors, such as steroid use, decreased renal
function and an abnormal GH–IGF1 axis. Those below age
6 years are the ones to benefit most from transplantation in
demonstrating acceleration in linear growth. Newer treat-
ment modalities targeting the GH resistance with recombi-
nant human IGF-1 (rhIGF-1), recombinant human IGFBP3
(rhIGFBP3) and IGFBP displacers are under investigation
and may prove to be more effective in treating growth
failure in CKD.
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Learning objectives:
(1) To review the normal growth pattern in childhood and
its alteration in chronic kidney disease.
(2) To understand the mechanisms believed to be respon-
sible for growth failure in chronic kidney disease.
(3) To understand the new evidence supporting therapy
for growth failure in chronic kidney disease.
(4) To identify targets for future therapies for treatment of
growth retardation in chronic kidney disease.
Introduction
Growth retardation is a common result of chronic kidney
disease (CKD) in childhood. Children with CKD fail to
achieve the final adult height consistent with their genetic
potential [1]. Data from the North American Pediatric
Renal Trials and Collaborative Studies (NAPRTCS) 2005
database revealed that 36.9% of children with CKD had
statutory growth impairment. Even though the growth
failure was correlated with the degree of renal impairment,
those with mild reduction of glomerular filtration rate
(GFR) also exhibited short stature. Children were short at
initiation of dialysis, with younger age associated with
more severe growth failure and little improvement in height
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e-mail: fkaskel@aecom.yu.edustandard deviation score (SDS). The mean height deficit for
all renal failure patients was −1.85 (less than the third
percentile of their healthy peers) at transplantation. This
deficit was greater for male patients and for younger
subjects. Those below age 6 years benefited most from
transplantation in demonstrating acceleration in linear
growth. For subjects aged 6–12 years, the linear growth
remained stable, and those older than 12 years of age had
no increase in their height deficit score [2–4].
Despite advances in medical care, growth failure in CKD
is associated with increased morbidity and mortality. Furth
et al. demonstrated from the United States Renal Data System
(USRDS) database that patients with severe-to-moderate
growth failure had increased hospitalization rates and
increased risk of death [5].
Growth retardation is assessed by the SDS or height
deficit score, which measures the patient’sh e i g h ti n
comparison with that of unaffected children of similar age.
Wong et al. demonstrated that, among pediatric patients on
dialysis or after transplantation, each SDS decrease in height
was associated with an increase in death by 14% [6].
Alteration of normal growth patterns in CKD
Linear growth is unique to childhood. Complex biological
processes are responsible for maintaining normal growth.
Infancy is the fastest growing period of childhood; one-
third of the total growth occurs in the child’s first 2 years of
life, and this is mainly nutrient dependant. This growth is
markedly decreased in congenital CKD, with the greatest
height deficit occurring in the child’s first year of life,
especially during the first 4 months [7]. Thus, the earlier the
onset of kidney disease, the more severe the growth
disturbance.
Additional factors affecting growth are inadequate
protein and calorie intake, water and electrolyte losses in
polyuric and salt wasting conditions, anemia, metabolic
acidosis, renal osteodystrophy, and resistance to hormones
mediating growth. Early nutritional intervention and pre-
vention of metabolic deficits of renal failure can preclude
the development of growth failure in this period. Conser-
vative treatment (no use of growth hormone) in pre-dialysis
patients from birth to 3 years, revealed a favorable growth
rate, with height velocity at 22.2 cm/year, 10.9 cm/year and
7.6 cm/year for each year, respectively, all of which were
higher than the lower two standard deviation scores [5].
Further discussion of these factors is beyond the scope of
this article.
During the mid-childhood period, a constant growth rate
of 5–7 cm/year is demonstrated, mainly under the control of
growth hormone (GH) and thyroid hormone. Children with
congenital CKD grow at the percentile achieved at the end
of 2 years of life. Even though one of the most important
predictors of growth impairment is the degree of renal
insufficiency, significant short stature has been seen at all
levels of renal function [3, 7].
At the onset of puberty, the growth hormone/insulin-like
growth factor (GH/IGF-1) axis is activated by small
increases in estrogen and testosterone in girls and boys,
respectively. The onset of puberty is delayed in adolescents
with CKD; peak height velocity is delayed by approxi-
mately 2.5 years. The pubertal growth spurt is delayed,
shortened and associated with a reduced growth velocity.
The pubertal height gain is about 65% of that seen in
healthy children without CKD and is likely due to the
shortened growth spurt [1]. These effects of delayed
puberty in CKD are mediated by a loss of the normal
pulsatile hypothalamic release of the gonadotropin-releas-
ing hormone (GnRH).
GH and IGF axis
Growth hormone is the key endocrine regulator of postnatal
growth (Fig. 1)[ 8]. The anterior pituitary secretes growth
hormone in a pulsatile manner stimulated by the growth
hormone releasing hormone (GHRH) and inhibited by
somatostatin. GH mediates its somatotropic actions directly
and mainly through IGF-1. Ghrelin, a growth hormone-
releasing peptide expressed in the stomach and hypothala-
mus, is involved in hormonal and nutritional regulation of
GH release [9].
Growth hormone and the IGF-1 axis play a major role in
growth failure in CKD. Random fasting serum levels of GH
are normal or increased in children and adults with CKD,
depending on the extent of renal failure. The half-life of GH
is prolonged, due to decreased metabolic clearance second-
ary to decreased functional renal mass in proportion to the
degree of renal dysfunction. A high normal calculated GH
secretion rate and amplified number of GH secretory bursts
have been reported in pre-pubertal children with end-stage
renal disease, likely due to attenuated IGF-1 feedback [8].
This has led to the concept of GH insensitivity or resistance
in uremia.
Pubertal patients with advanced CKD have a reduced GH
secretion rate, indicating altered sensitivity of somatotropic
hormones to the stimulatory effects of sex steroids [10].
GH resistance
GH receptors One mechanism for GH resistance is a
reduced density of GH receptors in target organs. Determi-
nation of the concentration of serum growth hormone
binding protein (GHBP), which is a cleaved product of the
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tissues, particularly liver, since GHBP is derived mainly,
but not exclusively, from the liver. GHBP is low in children
and adults with CKD and proportionate to the degree of
renal dysfunction. Serum GHBP correlates with both
spontaneous growth rate and response to GH therapy, and
it is an indirect indicator of sensitivity to both exogenous
and endogenous GH [11, 12]. However, there is controver-
sy as to the reliability of serum GHBP level as a marker of
GH receptor levels in specific tissues [13].
Janus kinase/signal transducer and activator of transcrip-
tion signaling Another mechanism for GH resistance in
uremia is a defect in post-receptor GH-activated Janus
kinase/signal transducer and activator of transcription
(JAK/STAT) signaling (Fig. 2)[ 14]. GH action is mediated
by the binding of GH to the growth hormone receptor
(GHR), resulting in its dimerization and the auto-phosphor-
ylation of the tyrosine kinases, Janus kinase 2 (JAK2),
which, in turn, stimulates phosphorylation of signaling
proteins, STAT proteins STAT1, STAT3 and STAT5. Upon
activation, these STAT proteins translocate to the nucleus
and activate GH-regulated genes. An intact JAK2-STAT5b
signaling pathway is essential for GH stimulation of IGF-1
gene expression. In uremia, a defect in the post-receptor
GH-activated JAK2 signal transducer and STAT transduc-
tion is described as one of the mechanisms of GH
resistance [14].
The JAK2/STAT pathway is regulated, among other
factors, by suppressor of cytokine signaling (SOCS)
proteins, which is induced by GH. These proteins bind to
JAK2 and inhibit STAT phosphorylation [15]. Up-regulation
of SOCS has been described in inflammatory states and may
play a similar role in CKD [16].
IGF and IGFBP Daughaday et al. proposed the somato-
medin hypothesis: GH leads to an increase in IGF-1
(formerly called somatomedin) c) from the liver, which, in
turn, reaches the growth plate to mediate its action [17].
However, it was later demonstrated that all the effects of
GH are not mediated through IGF-1. Also, the liver is not
the only source of IGF-1, and it is produced in other tissues.
Circulating IGF-1 mainly derived from the liver acts as an
endocrine hormone. IGF-1 produced locally acts as a
paracrine/autocrine hormone. The majority of circulating
IGF in the serum exists as a 150 kDa complex, including
the IGF molecule, IGF binding protein 3 (IGFBP3) and the
acid labile subunit (ALS). IGF-1 gene knockout in mice
results in miniature mice that die soon after birth. Knock-
out of IGF-1 in the liver alone results in relatively normal
sized mice with a 75% reduction in circulating IGF-1
levels, suggesting that local IGF-1 may be more important
for body growth than liver IGF-1 [18]. ALS knock-out mice
also exhibit relatively normal growth and development,
despite a 65% reduction in circulating IGF-1 levels.
Disruption of both liver IGF-1 and ALS genes results in
85–90% reduction in circulating IGF-1 levels and signifi-
cant reduction in linear growth, suggesting that a threshold
concentration of IGF-1 is necessary for normal growth [19].
IGF-1 is the predominant IGF during the rapid growth
period of puberty. The levels of IGFs (IGF-1 and IGF-2) are
normal in pre-terminal renal failure. In end-stage renal
disease IGF-1 level is normal or decreased and levels of
IGF binding proteins (IGFBP) are increased, thus resulting
in a net decrease in IGF bioactivity. Free IGF-1 is decreased
in proportion to renal failure [20, 21].
Fig. 1 GH/IGF-1 axis in CKD: deranged somatotropic axis in chronic
renal failure. The GH/IGF-I axis in CRF is changed markedly,
compared with the normal axis shown here. In CRF the total
concentrations of the hormones in the GH/IGF-I axis are not reduced,
but there is reduced effectiveness of endogenous GH and IGF-I, which
probably plays a major role in reducing linear bone growth. The
reduced effectiveness of endogenous IGF-I likely is due to decreased
levels of free, bioactive IGF-I as levels of circulating inhibitory IGF-
binding proteins (IGFBPs) are increased. In addition, less IGF-I is
circulating in the complex with acid labile subunit (ALS) and IGFBP-
3 as a result of increased proteolysis of IGFBP-3. Together, these lead
to decreased IGF-I receptor activation and a decreased feedback to the
hypothalamus and pituitary. Low free IGF-I and high IGFBP-1 and
IGFBP-2 levels probably contribute to reduced renal function and lead
to reduced stature. The direct effects of GH on bone, which are poorly
understood, also are blunted. Reprinted from [8] with permission
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receptor (IGF-1R) at the α subunit, where it activates
tyrosine kinase intrinsic to the IGF-1Rβ subunit. In
experiments with rats with CKD, skeletal muscles show
decreased serum levels of IGF-1 and IGF-1 mRNA, while
IGF-1R mRNA and IGF-1R numbers are increased, with
normal binding affinity. However, there is resistance to
post-receptor signal transduction; both auto-phosphoryla-
tion of the IGF-1R tyrosine kinase and activity of the IGF-
1R tyrosine kinase to the exogenous insulin receptor
substrate-1 (IRS-1), a natural substrate for IGF-1 receptor
tyrosine kinase, are diminished in skeletal muscle of CKD
rats. These abnormalities may account for the resistance of
IGF-1 to protein turnover in skeletal muscles in CKD [22].
IGFs are transported in plasma bound to IGF binding
proteins (IGFBPs), which are responsible for extending
their half-life and controlling their bioavailability. There are
six different IGFBPs, based on their respective amino acid
sequence. Of the IGFs in the serum, 75% circulate as a
ternary complex bound to IGFBP3 and another subunit,
acid labile subunit (ALS), to form major 150 kDa com-
plexes. This acts as a reservoir and cannot cross the
endothelial barrier. Some 20–25% of IGFs are present as
smaller binary complexes with other IGFBPs forming the
minor complex (35 kDa) [23]. Approximately 97% of IGF
is bound; 1% of IGF-1 is in a free bioactive form. In
healthy children there is a 25% excess of IGFBPs over IGF,
while, in pre-terminal renal failure, IGFBPs are 150% in
excess of IGFs, and in end-stage renal disease they are
200% in excess, thus reducing the bioavailability of IGF
[21].
IGFBP3 is the most abundant of all the binding proteins.
I G F B P 3a n dI G F B P 5a r es i m i l a ri nm a n ya s p e c t s ;
structurally, they are both closely related, both potentiate
IGF action and are up-regulated by GH. The serum level of
intact IGFBP3 is normal in CKD, while the fragmented
Fig. 2 Growth hormone-mediated JAK/STAT signal transduction. GH
activates several signaling pathways via JAK2, including the JAK/
STAT pathway [22, 23]. Binding of GH to its receptor (GHR) activates
JAK2, which then self-phosphorylates. This is followed by phosphor-
ylation of the GHR and, subsequently, STAT 1a, STAT 3, STAT 5a,
and STAT 5b, members of a larger family of cytoplasmic transcription
factors. These phosphorylated STATs form dimers that enter the
nucleus, where they bind to specific DNA sequences and activate their
target genes, IGF-1 and some suppressors of cytokine signaling
(SOCS). Deletion of STAT5 expression leads to retarded body growth,
and STAT5b is required for GH-mediated IGF-1 gene expression. In
renal failure phosphorylation of JAK2 and the downstream signaling
molecules STAT5, STAT3, and STAT1 is impaired, as are the nuclear
levelsofphosphorylatedSTATproteins.ThisimportantcauseofuremicGH
resistance may result, in part, from up-regulation of SOCS2 and SOCS3
expression with suppressed GH signaling and also from increased protein
tyrosine phosphatase activity, with enhanced dephosphorylation and
deactivation of the signaling proteins. Reprinted from [14] with permission
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peptides [24]. IGFBP5 level is not altered, but it exists
mostly in the fragmented form.
Intact IGFBP1, IGFBP2, IGFBP4 and IGFBP6 are
elevated in CKD in relation to the degree of renal
dysfunction [25]. IGFBP1, IGFBP2 and IGFBP6 are
growth inhibitors of IGF-dependant proliferation of chon-
drocytes. Increased levels of IGFBP1 and IGFBP2 have
been shown to correlate negatively with height [26].
Ulinski et al. analyzed serum levels of IGFBP4 and
IGFBP5 in 89 CKD patients. There was a fourfold increase
in IGFBP4, while IGFBP5 was not significantly increased.
IGFBP4 level was inversely correlated with glomerular
filtration rate and standard height. IGFBP5 level was
positively correlated with standard height [25].
Ghrelin
Ghrelin is a newly discovered, 28-amino acid peptide, with
growth hormone releasing properties [growth hormone
secretagogue (GHS)], expressed most abundantly in the
stomach and also in smaller quantities by pancreatic islet
cells and hypothalamus. Ghrelin levels are increased by
fasting, cholinergic stimulation, estrogen and recombinant
hIGF-1, and are decreased by food intake [27].
Ghrelin has been shown to increase the release of GH
which is amplified by co-administration of GHRH, and acts
at the level of the hypothalamus and pituitary. The role of
ghrelin in the growth abnormalities in CKD has yet to be
defined.
Treatment with recombinant human growth hormone
Studies in the past have shown that therapy with recombi-
nant human growth hormone (rhGH) in CKD is safe and
efficacious, and that it increases growth rate and improves
standardized height [28, 29]. Haffner et al. studied the
effect of growth hormone treatment on final adult height of
children with CKD (Fig. 3)[ 1]. In contrast to the controls
that had persistent growth failure, children treated with
rhGH demonstrated sustained catch-up growth. In treated
children the standardized height increased from baseline to
a mean final adult height of 1.6±1.2 SD below normal,
while, in untreated control children, it decreased from
baseline to a mean final adult height of 2.1±1.2 SD below
normal. Of the children treated with rhGH, 65% reached a
final adult height within the normal range, although it was
significantly below the genetic target [1].
Poor growth outcomes after renal transplantation are
associated with corticosteroid use, persistent CKD and
abnormalities in the GH-IGF-1 axis. The use of rhGH after
transplantation leads to catch-up growth associated with
increase in IGF-1 levels [26]. Using the NAPRTCS
database of 513 renal transplant recipients receiving rhGH,
Fine and Stablein demonstrated that final adult height was
superior in rhGH treated patients compared to controls.
Fig. 3 Growth hormone treat-
ment in chronic kidney disease:
change from initially predicted
adult height at baseline in 38
children (32 boys and six girls)
with chronic renal failure who
received growth hormone treat-
ment compared with 50 control
children with chronic renal fail-
ure who did not receive growth
hormone, according to gender.
Values are means ± SD. Aster-
isks indicate significant differ-
ences from the previous period
(P<0.001) and daggers indicate
significant differences from the
children who were not treated
with growth hormone (P<
0.001). Reprinted from [1] with
permission
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both groups, with no increase in adverse events [30].
RhGH treatment in renal failure is associated with an
elevation in serum free IGF-1 [31]. RhGH increases
IGFBP3, IGFBP4, and IGFBP5, decreases IGFBP1 and
has no effect on IGFBP2 and IGFBP6. RhGH also increases
IGFBP4, but does not correlate with change in height SDS,
since most of the IGFBP4 in serum is fragmented [25, 31].
RhGH-mediated increase in IGFBP3, IGFBP5 and ALS
results in increased ternary complexes and correlates
positively with the increment in height SDS [31].
Among the growth-promoting effects of treatment with
rhGH in CKD are anabolic effects, demonstrated by
increase in body weight and mid-arm muscle circumfer-
ence. The recommended dose approved for treatment of
growth failure in CKD is 0.35 mg/kg per week (28 IU/m
2
per week) [3].
Targets for future therapy:
Treatment with recombinant IGF-1
The GH resistance associated with CKD may be amenable
to treatment with recombinant human IGF-1 (rhIGF-1). In
children with GH-receptor deficiency or GH-inactivating
antibodies, rhIGF-1 treatment resulted in a modest increase
in growth velocity and height SDS, although less than that
expected with rhGH [32].
In addition, short-term administration of rhIGF-1 has
been shown to increase glomerular filtration rate and renal
plasma flow in patients with end-stage renal disease and in
healthy subjects. Vijayan et al. demonstrated sustained
improvement in renal function in a 31-day randomized,
double-blinded, placebo-controlled trial of 15 patients with
advanced CKD, who had received intermittent doses of
rhIGF-1 [33].
One reason for the use of IGF-1 treatment in CKD is that
while patients are GH sufficient, they are GH resistant.
Therefore, rhIGF-1 may be more beneficial than GH as
therapy in CKD and merits further investigation as an agent
for treatment of growth failure and improvement in renal
function in CKD [34].
Combined use of rhGH and rhIGF-1
Animal studies have shown that the combined use of rhGH
and rhIGF-1 has an independent and additive effect. While
whole-body growth in uremic rats was similar with
treatment with either agent, an additive effect on longitu-
dinal growth and anabolism was demonstrated when both
agents were administered together [35].
Combined use of rhIGF-1 and rhIGFBP3
One of the concerns with the use of rhIGF-1 in children with
normal GH production is that rhIGF-1 may suppress
endogenous GH, IGFBP3 and ALS production, which may
have a detrimental effect on growth. The other adverse effect
of the use of rhIGF-1 observed in GH receptor-deficient
patients is hypoglycemia, due to low levels of IGFBP3 and
increased level of free IGF-1 available for binding to insulin
receptors [32]. Both these effects can be reduced by the
combined use of rhIGF-1 and rhIGFBP3 [36].
IGFBP displacers
At least two different IGF-1 analogs have been made,
which have an affinity for IGFBPs but have no effect on
IGF receptors, thus “displacing” IGF-1 from IGFBPs and
elevating free IGF-1 levels. Animal studies in hypophysec-
tomized rats and dwarf dw/dw rats treated with IGFBP
displacers demonstrated increased kidney size, improved
renal function, and the stimulation of weight gain and bone
growth. This effect was enhanced when treatment with
IGFBP displacers was combined with rhIGF-1 [37].
Conclusion
This review of the literature lends support to the concept
that CKD is associated with GH “resistance”. Despite
adequate treatment with rhGH and improvement in catch-up
growth, children with CKD display a final adult height that
is often below the genetic target. The potential for newer
therapies with rhIGF-1, combined use of rhGH and rhIGF-1,
combined use of rhIGF-1 and rhIGFBP3 or IGFBP
displacers to improve both the short and long term outcomes
in the treatment of the disturbances in the GH/IGF-1 axis in
CKD awaits future investigations.
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Questions (answers appear after the reference list)
1. All the factors mentioned below are causes of growth
failure in chronic kidney disease except
(a) increased sensitivity to hormones mediating
growth
(b) anemia
(c) metabolic acidosis
46 Pediatr Nephrol (2008) 23:41–48(d) inadequate caloric intake
(e) renal osteodystrophy.
2. What are the mechanisms of growth hormone resis-
tance in uremia?
(a) increased GH receptor density in target organs
(b) defect in post-receptor JAK/STAT signaling
(c) growth hormone deficiency
(d) increased IGFBPs and decreased free IGF-1 levels
3. How does treatment with growth hormone modify the
altered GH-IGF1 axis?
(a) increased GH levels in serum
(b) increased IGF-1 levels
(c) decreased IGFBP1
(d) increased IGFBP5.
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